Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Cidara Therapeutics Inc
CDTX | US
11.22
USD-0.04
-0.36%
CDTX | US
About Cidara Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
11.22
Open
11.49
High
11.49
Low
11.07
Cidara Therapeutics Inc. a biotechnology company focuses on the discovery development and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections including candidemia and invasive candidiasis which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections such as RSV HIV and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics Inc. and changed its name to Cidara Therapeutics Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego California.
View LessCDTX | US
Risk
39.0
Sharpe
-0.61
Luna's Score
42/100
Recommendation
Sell
Luna says (CDTX | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
46.7%1 month
39.0%3 months
46.5%6 months
74.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
5.75
Price to book
0.60
Debt to equity
0.03
Debt to assets
0.02
Ent. to EBITDA
-1.64
Ent. to rev.
0.61
PEG
-
Other Fundamentals
EBITDA
-30.11M
MarketCap
78.97M
MarketCap(USD)
78.97M
Div. yield
-
Op. margin
-3.68K
Erngs. growth
-
Rev. growth
-94.10
Ret. on equity
-153.39
Short ratio
4.31
Short perc.
1.31
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
1.44
Range1M
1.44
Range3M
3.23
Volumes: Market Activity
Rel. volume
0.93
Price X volume
187.69K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.64 | - | Cheaper |
| Ent. to Revenue | 0.61 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.60 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 46.55 | - | Lower Risk |
| Debt to Equity | 0.03 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 78.97M | - | Emerging |
